About | Free Trial

Last Update

2016-08-02T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Renier Brentjens?

Dr. Renier Brentjens J.

Chief of the Cellular Therapeutics Center

MSKCC

HQ Phone: (212) 639-2000

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

MSKCC

1275 York Avenue

New York, New York 10065

United States

Company Description

MSKCC is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Our speciali ... more

Find other employees at this company (13,802)

Background Information

Affiliations

Director, Cellular Therapeutics
Sloan-Kettering Cancer Center

Member of Laboratory
The Chemotherapy Foundation

Member of Laboratory
Sadelain

Education

MD

SUNY Buffalo

Web References (167 Total References)


The NCI cites Renier J. ...

immuno-oncologynews.com [cached]

The NCI cites Renier J. Brentjens, M.D., Ph.D. , of Memorial Sloan Kettering Cancer Center (MSKCC) in New York observing that results from the trials performed thus far are proof of principle that we can successfully alter patients T cells so that they attack their cancer cells. Dr. Brentjens notes that in light of encouraging results in mouse studies, he and research colleagues at his Memorial Sloan Kettering lab are now testing this approach at in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia who are no longer responsive to chemotherapy. "These highly innovative studies will hopefully result in a novel and successful treatment option for patients with certain forms of hematologic cancers," he says.

In an OncLive video, Dr. Brentjens explains how immune cells (T cells) are naturally programmed to be able to distinguish between self and nonself cells, which express foreign proteins, and how once detected, T cells attack and kill foreign cells. He notes that that an idea central to immunotherapy is to "reeducate" T cells to make them recognize cancer cells as being foreign.


Terry Fox Run

www.katesteam.org [cached]

Dr. Brentjens, MSKCC

...
Every single cent we raise - over $150,000 to date - goes to cancer research conducted by Dr. Renier Brentjens at Memorial Sloan Kettering Cancer Center.


TFR '07 Highlights

www.katesteam.org [cached]

Dr. Brentjens, MSKCC

...
Dr. Renier Brentjens, MSKCC
Kate's Team ® Copyright 2000 - 2016. All rights reserved.


TFR '08 Highlights

www.katesteam.org [cached]

Dr. Brentjens, MSKCC

...
This year's fundraising efforts brought us to an incredible achievement - we have now raised over $150,000 for clinical trials conducted by Dr. Renier Brentjens! An amazing accomplishment - thank you for your dedication!
Many people are interested in knowing exactly where the money goes - as we all know, every single cent donated goes straight to clinical trials at Memorial Sloan Kettering , the world's largest and oldest cancer center. The money that Kate's Team® has raised helps fund research by Dr. Renier Brentjens, who is studying alternative treatment approaches to eradicate tumor cells in patients with chronic lymphocytic leukemia (CLL).


But the results from the trials ...

www.stemcelldoctors.org [cached]

But the results from the trials performed thus far are proof of principle that we can successfully alter patients T cells so that they attack their cancer cells, said one of the trial's leaders, Renier J. Brentjens, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center (MSKCC) in New York.

Adoptive cell transfer is like giving patients a living drug, continued Dr. Brentjens.
...
Dr. Brentjens agreed that both drugs could become a useful way to help manage cytokine-release syndrome because, unlike steroids, they dont appear to affect the infused CAR T cells activity or proliferation.
...
Research groups like Dr. Brentjens are also working to make a superior CAR T cell, including developing a better receptor and identifying better targets.

Similar Profiles

Other People with this Name

Other people with the name Brentjens

Christopher Brentjens
Saint Peter's Prep

Cas Brentjens
Infor Inc

Sjoerd Brentjens
ENEXIS Ltd.

Tricia Brentjens
NY Presbyterian Hospital-Columbia University Medical Center

Joanneke Brentjens
Fresenius Kabi USA LLC

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory